Methylprednisolone acetate clinical trials
Methylprednisolone acetate is named as an intervention in 2 current clinical trials in our Netherlands and Turkey registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Sint Maartenskliniek (1). The most-studied condition is Hand Osteoarthritis.
Where Methylprednisolone acetate is approved
All regulators →Of the three regulators tracked here, the first to approve Methylprednisolone acetate was the US, on 24 Oct 1957.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Methylprednisolone acetate
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Methylprednisolone acetate works
All drug targets →- Glucocorticoid receptor agonist AgonistTarget: NR3C1 nuclear receptor subfamily 3 group C member 1✓ In ChEMBL and the Guide to Pharmacology
- Bell's palsyPhase 3
- COVID-19–associated multisystem inflammatory syndrome in childrenPhase 3
- Acoustic neuromaPhase 3
- Acute myeloid leukemiaPhase 3
- Acute respiratory distress syndromePhase 3
- Ischemic strokePhase 3
- Sudden sensorineural hearing lossPhase 3
- COVID-19Phase 2
- HeadachePhase 2
- Acute graft versus host diseasePhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201081, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 7088, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Methylprednisolone acetate
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 7 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Methylprednisolone acetate
- ChEMBL
- CHEMBL1201081
- PubChem CID
- 23680530
- CAS number
- 2375-03-3
- FDA UNII
- LEC9GKY20K
- Wikidata
- Q27282942
- Wikipedia
- Methylprednisolone succinate
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Methylprednisolone acetate
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis
NCT07371572 · ClinicalTrials.gov ↗ · Hand Osteoarthritis
|
Phase 3 | Recruiting | Sint Maartenskliniek | Netherlands |
|
Comparative Effectiveness of Ultrasound-Guided Tenoxicam and Corticosteroid Injections for Lateral Epicondylitis
NCT07883876 · ClinicalTrials.gov ↗ · Lateral Epicondylitis
|
Not applicable | Not yet open | Ankara Etlik City Hospital | Turkey |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Methylprednisolone acetate
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Sint Maartenskliniek | 1 |
| Ankara Etlik City Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Turkey | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Methylprednisolone acetate trials
How many clinical trials are testing Methylprednisolone acetate?
2 current trials in our Netherlands and Turkey registers name Methylprednisolone acetate as a drug or biological intervention, as of the registry sync on 23 October 2026. Completed and withdrawn studies are not counted.
Are Methylprednisolone acetate trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Methylprednisolone acetate clinical trials?
Sint Maartenskliniek (1) and Ankara Etlik City Hospital (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Methylprednisolone acetate works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Methylprednisolone acetate works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Methylprednisolone acetate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 23 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.